Financial News
Articles published by TransCode Therapeutics, Inc.
Via GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
March 28, 2024
Via GlobeNewswire
Tickers
RNAZ
Via GlobeNewswire
Tickers
RNAZ
Via GlobeNewswire
Tickers
RNAZ
Via GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
January 11, 2024
Via GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
January 04, 2024
Via GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
December 05, 2023
Via GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
November 14, 2023
Via GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Public Offering of Common Stock
October 26, 2023
Via GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
September 28, 2023
Via GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Announces Pricing of $8 Million Public Offering
September 25, 2023
Via GlobeNewswire
Tickers
RNAZ
TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update
August 14, 2023
Via GlobeNewswire
Tickers
RNAZ
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.